PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Deutivacaftor→

Deutivacaftor PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1413431-07-8
Molecular formula
C24H19D9N2O3
Molecular weight
401.5 g/mol
Drug class
CFTR potentiatordeuterated ivacaftor component of vanzacaftor/deutivacaftor/tezacaftor combination
Mechanism of action
Enhances the open probability of cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels at the cell surface. Deuteration modifies metabolic stability; its clinical use is as part of a fixed triple combination, not as a standalone API.
Indications / reported uses
  • Component of the fixed combination ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) for treatment of cystic fibrosis in eligible patients aged 6 years and older who have at least one responsive CFTR mutation, under the current product label

Sources: US DailyMed — ALYFTREK prescribing information · US FDA — ALYFTREK approval · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Deutivacaftor PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Deutivacaftor Permitted Daily Exposure (PDE) report (the Deutivacaftor PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Deutivacaftor Occupational Exposure Limit (OEL) report (the Deutivacaftor OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.